Notably, majority targets of TB-2 are implicated in tumor therapy, including TGM2 (Zhang et al., 2023), KIT (Meng and Carvajal, 2019), EGFR (Zubair and Bandyopadhyay, 2023), AURKA (Du et al., 2021), FASN (Fhu and Ali, 2020), and CDK2 (Tadesse et al., 2020), which have garnered extensive research attention. Here, EGFR is linked to neoplasm.